2.1 | Patient Composition
A retrospective review of pre-transplant RV PCR, symptom screening, and clinical outcomes was done for all patients receiving allogeneic HSCT from June 1 2016 to March 31 2023 at Children\RL’s National Hospital in the District of Columbia (D.C.). All types of allogeneic stem cell sources were included in the study, such as bone marrow (BM), cord blood, peripheral blood stem cells (PBSC), and combinations. Autologous transplants were excluded. Patients missing one or both of their pre-transplant RV PCR tests were excluded from the study. Patients who received more than one HSCT in this time had their second transplant excluded if it was received within 100 days of their first transplant and/or if the second transplant was done within the same hospital admission, as they would not have received appropriate RV PCR testing for the study. Patients with severe combined immunodeficiency (SCID) as an indication for transplant were also excluded due to the higher likelihood of an RV-positive result and poorer post-transplant outcomes. Patients who met all criteria were identified using the bone and marrow transplant department\RL’s patient database. If patients were intentionally delayed based on an RV PCR result, the RV PCR results used in this study were the last pre-transplant one before admission. Online medical records were obtained and reviewed to collect relevant information from the time of the first pre-admission RV PCR to 100 days post-transplant.